Blood-brain Transportable Peptides

Abstract

Cognitive dysfunction is a serious and worldwide social issue that reduces quality of life. Despite extensive research, appropriate for ameliorating cognitive dysfunction have not yet been developed. Signs of the Alzheimer's disease may become apparent 10‐20 years before a definitive clinical diagnosis, and these are due to impairment of the acetylcholine nerve system due to amyloid β accumulation in the brain. Thus far, some human and animal studies have reported that intake of certain peptides can delay the onset of dementia. However, few evidential in vivo studies have shown that peptides can be transported across the blood-brain barrier (BBB) in intact form. In this review, we discuss BBB-transportable peptides and their potential to improve amyloid β-induced memory dysfunction.